All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Fast Track Status to Selinexor for Myelofibrosis

July 19th 2023

The FDA has granted a fast track designation to selinexor for use in the treatment of patients with myelofibrosis, including primary myelofibrosis, post–essential thrombocytopenia myelofibrosis, and post–polycythemia vera myelofibrosis.

IMX-110 Plus Tislelizumab Leads to Tumor Shrinkage in Heavily Pretreated mCRC

July 19th 2023

Treatment with the combination of the tissue-specific therapeutic IMX-110 and the anti–PD-1 antibody tislelizumab led to tumor shrinkage in heavily pretreated patients with metastatic colorectal cancer.

Lazertinib Outperforms Gefitinib in EGFR-Mutated NSCLC

July 18th 2023

The third-generation EGFR TKI lazertinib displayed a significant efficacy improvement compared with gefitinib in patients with EGFR-mutated advanced non–small cell lung cancer when given in the first-line.

Combination Approaches Are on the Horizon in Later-Line HER2+ Breast Cancer Management

July 18th 2023

Adrienne G. Waks, MD, spotlights the need to understand mechanisms of resistance to second-line HER2-positive breast cancer therapies, chemotherapy-free regimens with later-line treatment potential, and the future of HER2-positive disease management.

Breast Cancer Research Breakthroughs Signal Paradigm Shifts Across Disease Subsets

July 18th 2023

Maryam Lustberg, MD, MPH, discusses insights regarding other key breast cancer data presented at the 2023 ASCO Annual Meeting, including findings from the phase 3 BWEL trial, updated data from the phase 2 ELAINE-2 trial, and the final overall survival analysis of the phase 3 TROPiCS-02 trial.

Westin Highlights Key Clinical Trial Updates from ASCO 2023 in Ovarian Cancer and Gynecologic Oncology

July 18th 2023

Shannon Westin, MD, MPH, FACOG, expands on key clinical trial updates in gynecologic oncology shared at the 2023 ASCO Annual Meeting and highlights what she is looking forward to seeing in the future of care for patients with gynecologic malignancies.

Frontline SHR-1701 Plus BP102 and Chemo Shows Potent Activity in Cervical Cancer

July 18th 2023

The novel bifunctional fusion protein SHR-1701 combined with standard first-line treatment with the bevacizumab biosimilar BP102 and platinum-doublet chemotherapy produced high, durable responses and was deemed tolerable in patients with cervical cancer.

Setanaxib Plus Pembrolizumab Elicits PFS Benefit in Recurrent or Metastatic HNSCC

July 18th 2023

The combination of the NOX1/4 inhibitor setanaxib and pembrolizumab produced progression-free survival benefits compared with placebo plus pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

CB-010 Elicits 94% ORR in Relapsed/Refractory Non-Hodgkin Lymphoma

July 18th 2023

The allogeneic CAR T-cell therapy CB-010 demonstrated early signs of durable antitumor activity and favorable safety in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Loss of Y Chromosome in Men Enables Cancer to Grow

July 18th 2023

Cedars-Sinai Cancer investigators elucidate how this process allows bladder tumors to evade the immune system but also makes them vulnerable to a common treatment.

FDA Awards Orphan Drug Designation to Gallium Maltolate for Pediatric Glioblastoma Multiforme

July 18th 2023

The FDA has granted an orphan drug designation to gallium maltolate for use as a potential therapeutic option in pediatric patients with glioblastoma multiforme.

Luke Breaks Down Key Clinical Trial Updates From the 2023 ASCO Annual Meeting

July 17th 2023

Jason Luke, MD, FACP, discusses key takeaways from the KEYNOTE-716 and KEYNOTE-942 trials and other key updates from across the melanoma landscape presented at the 2023 ASCO Annual Meeting.

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17th 2023

Patients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic renal cell carcinoma.

HER2+ Breast Cancer Treatment Arena May Redefine the Roles of ADCs and Targeted Agents

July 17th 2023

Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape.

NOX-A12 Plus Radiotherapy and Bevacizumab Produces Responses in Previously Untreated Glioblastoma

July 17th 2023

The addition of the CXCL12 inhibitor NOX-A12 to standard-of-care radiotherapy and bevacizumab elicited responses when used as first-line treatment in patients with glioblastoma, according to updated data from the expansion arm of the phase 1/2 GLORIA trial.

Amivantamab Plus Chemotherapy Improves PFS in EGFR Exon 20–Mutant NSCLC

July 17th 2023

Amivantamab-vmjw plus carboplatin and pemetrexed led to a clinically meaningful and statistically significant improvement in progression-free survival vs carboplatin and pemetrexed alone in patients with newly diagnosed advanced or metastatic EGFR exon 20 insertion–mutated non–small cell lung cancer.

World-Renowned Biochemist Joins Sylvester Comprehensive Cancer Center

July 17th 2023

One of the world’s foremost biochemists is joining Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, bringing decades of groundbreaking research in genetics, epigenetics and cellular processes.

EMA Accepts Marketing Application for Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma

July 17th 2023

The European Medicines Agency has accepted a marketing authorization application seeking the approval of zolbetuximab for first-line treatment of patients with Claudin18.2-positive, HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

FDA Accepts NDA for Rivoceranib Plus Camrelizumab in Unresectable HCC

July 17th 2023

The FDA has accepted for review a new drug application seeking the approval of rivoceranib in combination with camrelizumab as a first-line treatment option for patients with unresectable hepatocellular carcinoma.

DecisionDx-Melanoma 31-Gene Expression Profile Test Stratifies Patients With Cutaneous Melanoma

July 17th 2023

The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.